



## PPD's Dr. Henrietta Ukwu Honored as Influential Leader for Pioneering Work in Global Regulatory Affairs

### Named to *PharmaVOICE* 100 List of Most Inspiring Leaders in the Life Sciences Industry

WILMINGTON, N.C., (August 1, 2011) - PPD, Inc. (Nasdaq: PPD) today announced that Dr. Henrietta Ukwu, senior vice president for global regulatory affairs, has been named to the 2011 *PharmaVOICE* 100 list of the most inspiring people in the life sciences industry.

The honor from *PharmaVOICE* magazine recognizes Dr. Ukwu's contributions in providing innovative leadership in the area of [regulatory affairs](#) in the endeavor of delivering life-changing medicines for people in need. An internist and infectious disease physician, Dr. Ukwu has extensive global regulatory experience across many biopharmaceutical therapeutic platforms and geographic regions.

"I am honored to be named to the *PharmaVOICE* 100," Dr. Ukwu said. "It is humbling to be recognized for the initiatives I've championed and for my efforts to teach and mentor rising leaders in the life sciences industry."

Now in its seventh year, the *PharmaVOICE* 100 is an annual list of individuals recognized for their contributions to the life sciences industry. The honorees are nominated by thousands of *PharmaVOICE* readers.

"The *PharmaVOICE* 100 are individuals who think outside the box, pioneer new paths to success and inspire their colleagues in the industry; they translate industry issues into opportunities and take the time to mentor the next generation of leaders in the life sciences arena," said Taren Grom, editor-in-chief and cofounder of *PharmaVOICE*. "Dr. Ukwu's demonstrated vision, leadership, and passion for impacting humanity through the pharmaceutical and CRO industry make her a great leader and role model."

Dr. Ukwu captured the evolution of the life sciences industry and regulatory profession, as well as the crucial and strategic role of regulatory teams in fostering success, in her new book, *Global Regulatory Systems: A Strategic Primer for Biopharmaceutical Product Development and Registration*. The book, published by CenterWatch, is a comprehensive reference guide for navigating the complexities of regulatory systems for product development, approval and registration around the world.

Prior to joining PPD, Dr. Ukwu held senior management positions in regulatory affairs at Pfizer, Inc., Wyeth Pharmaceuticals, Inc., and Merck & Co., Inc. She was involved in numerous product development activities and directly led the successful original regulatory development and filings of 14 new products, all approved.

#### About PPD

PPD is a leading global [contract research organization](#) providing [drug discovery](#), development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 44 countries and more than 11,000 professionals worldwide, PPD applies [innovative technologies](#), [therapeutic expertise](#) and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit <http://www.ppd.com/>.

*Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about Dr. Ukwu's contributions to PPD, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors which could cause future results to differ materially include the following: the ability to attract, integrate and retain key personnel, including a new CEO; competition in the outsourcing industry; PPD's ability to win new business; rapid technological advances that make our services less competitive; compliance with drug development regulations; changes in the regulation of the drug development process; overall global economic conditions; economic conditions in the pharmaceutical, biotechnology and government-sponsored research sectors; research and development spending in the pharmaceutical, biotechnology and government-sponsored research sectors; outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; actual operating performance; fluctuations in currency exchange rates; risks associated with and dependence on strategic relationships; risks associated with fixed price*

*contracts and cost overruns; international economic and political risks; and the ability to control SG&A spending. These and other PPD risk factors are set forth in more detail from time to time in our SEC filings, copies of which are available free of charge upon request from PPD's investor relations department. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD's estimates or views as of any date subsequent to the date hereof.*

**Contacts**

Media:

Ned Glascock

+910 558 8760

[ned.glascock@ppdi.com](mailto:ned.glascock@ppdi.com)

Analysts/Investors:

Luke Heagle

+910 558 7585

[luke.heagle@ppdi.com](mailto:luke.heagle@ppdi.com)